全文获取类型
收费全文 | 10502篇 |
免费 | 1135篇 |
国内免费 | 724篇 |
专业分类
耳鼻咽喉 | 113篇 |
儿科学 | 204篇 |
妇产科学 | 101篇 |
基础医学 | 1244篇 |
口腔科学 | 176篇 |
临床医学 | 1407篇 |
内科学 | 1580篇 |
皮肤病学 | 99篇 |
神经病学 | 552篇 |
特种医学 | 362篇 |
外国民族医学 | 5篇 |
外科学 | 1165篇 |
综合类 | 1766篇 |
现状与发展 | 4篇 |
预防医学 | 878篇 |
眼科学 | 233篇 |
药学 | 1081篇 |
10篇 | |
中国医学 | 560篇 |
肿瘤学 | 821篇 |
出版年
2024年 | 48篇 |
2023年 | 175篇 |
2022年 | 473篇 |
2021年 | 568篇 |
2020年 | 427篇 |
2019年 | 361篇 |
2018年 | 420篇 |
2017年 | 380篇 |
2016年 | 355篇 |
2015年 | 525篇 |
2014年 | 657篇 |
2013年 | 597篇 |
2012年 | 787篇 |
2011年 | 897篇 |
2010年 | 542篇 |
2009年 | 416篇 |
2008年 | 512篇 |
2007年 | 549篇 |
2006年 | 546篇 |
2005年 | 491篇 |
2004年 | 333篇 |
2003年 | 296篇 |
2002年 | 263篇 |
2001年 | 235篇 |
2000年 | 249篇 |
1999年 | 234篇 |
1998年 | 112篇 |
1997年 | 146篇 |
1996年 | 94篇 |
1995年 | 101篇 |
1994年 | 92篇 |
1993年 | 63篇 |
1992年 | 61篇 |
1991年 | 57篇 |
1990年 | 58篇 |
1989年 | 42篇 |
1988年 | 44篇 |
1987年 | 28篇 |
1986年 | 15篇 |
1985年 | 22篇 |
1984年 | 19篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1979年 | 5篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1969年 | 3篇 |
1968年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
API2-MALT1融合基因变异体在粘膜相关淋巴组织结外边缘区B细胞淋巴瘤中的分布及凋亡的关系 总被引:2,自引:0,他引:2
目的探讨API2-MALT1融合基因变异体在粘膜相关淋巴组织结外边缘区B细胞淋巴瘤(extranodal marginal zone B—cell lymphoma of mucosa—associated lymphoid tissue,MALT)中的分布特点及其转录与肿瘤凋亡的关系。方法将逆转录-聚合酶链反应和巢式聚合酶链式反应结合,检测62例不同部位MALT淋巴瘤中API2-MALT1融合基因的多种变异体;通过TdT介导脱氧核苷酸缺口末端标记技术进行肿瘤细胞的原位凋亡检测;通过逆转录-聚合酶链反应和免疫组化染色检测API2的mRNA和蛋白水平。结果62例MALT淋巴瘤中28例检出API2-MALT1融合基因(45.16%),为变异体A1446-M1123或A1446-M814,但未检出A1446-M541和A1446-M1150。A1446-M1123(18/28)的检出明显多于A1446-M814(10/28)。融和基因转录在甲状腺MALT淋巴瘤中检出最低,在其它部位的分布无差异。在API2-MALT1^ 组(API2-MALT1mRNA表达阳性组)肿瘤凋亡水平明显高于API2-MALT1^-组(API2-MALT1mRNA表达阴性组),API2的mRNA和蛋白水平低于阴性组。A1446-M1123^ 与A1446-M814^ 病例之间凋亡和API2的变化无差异。结论MALT淋巴瘤中t(11;18)(q21;q21)的发生有部位差异,A1446-M1123可能是中国人MALT淋巴瘤中API2-MALT1融合基因变异体的主要类型。API2-MALT1融合基因转录与MALT淋巴瘤的凋亡水平和API2的变化有关。 相似文献
22.
应用PCR技术检测恙螨体内恙虫病立克次体动态和经卵传递的研究 总被引:7,自引:0,他引:7
本文应用聚合酶链反应技术检测恙虫病立克次体实验感染的恙螨体内立克次体的动态变化,通过人工腹腔接种而感染的恙螨成虫,恙虫病立克次体至少能在其体内生存360天和经卵传递4代;通过未食幼虫叮咬病小鼠而感染的恙螨,经饱蚴、若蛹、若虫、成蛹和成虫阶段,恙虫病立克次体检测均呈阳性,至少能在成虫期体内生存270天和经卵传递1代。 相似文献
23.
24.
Inhibition of experimental autoimmune tubulointerstitial nephritis in Brown-Norway rats by (15S)-15-methyl prostaglandin E1. Analysis of the effect of prostaglandin E1 on the induction of the humoral immune response and the elicitation of humorally mediated inflammation. 下载免费PDF全文
Brown-Norway (BN) rats develop tubulointerstitial nephritis (TIN) after immunization with bovine tubular basement membrane (TBM) and adjuvants. Daily subcutaneous injections (either on Days 0-7 or Days 0-14) of (15S)-15-methyl prostaglandin E1 (M-PGE1) at a dose of 1 mg/kg/day markedly inhibited or completely abrogated the development of both the acute polymorphonuclear (Day 10) and the subsequent mononuclear (Day 14) inflammatory phases of BN rat TIN. Circulating anti-TBM antibody in Days 0-7 M-PGE1-treated rats was moderately diminished on Day 8 after immunization but not on Day 14. Circulating anti-TBM antibody in Days 0-14 M-PGE1-treated rats was only slightly diminished on Day 14. In experiments to test the effect of M-PGE1 on the elicitation phase of humorally mediated inflammation, M-PGE1 inhibited the acute inflammatory response observed 6 hours after intradermal injection of particulate TBM into TBM-sensitized BN rats. The inflammation in these skin tests was demonstrated by passive transfer experiments to be humorally mediated. The inhibition of acute humorally mediated intradermal inflammation was not attributable to neutropenia, because M-PGE1 caused a significant neutrophilia as demonstrated by peripheral blood smears. Although the inhibition of TIN in Days 0-14 M-PGE1-treated rats may have been due, in part, to dysfunction of the elicitation phase of humorally mediated inflammation, the inhibition of TIN in Days 0-7 M-PGE1-treated rats was more likely secondary to the diminished induction of either humoral or cellular immunity. 相似文献
25.
26.
A total nine hybridoma cell lines that produced monoclonal antibodies against thermostable direct hemolysin (Vp-TDH), a possible pathogenic toxin, of Kanagawa phenomenon-positive Vibrio parahaemolyticus was isolated and characterized. These monoclonal antibodies (mAbs) were divided into a minimum of five different specificity groups, including mAbs specific to Vp-TDH and common to Vp-TDH and Vp-TRH, a Vp-TDH-related hemolysin produced by Kanagawa phenomenon-negative V. parahaemolyticus. An enzyme-linked immunosorbent assay (ELISA) using mAb-1-D, a mAb specific for Vp-TDH, was developed for specific detection of Vp-TDH. On the other hand, the ELISA using mAb-9-D, and mAb common to both Vp-TDH and Vp-TRH, could be used for detection of both Vp-TDH and Vp-TRH. Thus, by combining these two ELISAs differential detection of Vp-TDH and Vp-TRH can be performed. Hence, the two ELISAs were applied for various strains of V. parahaemolyticus and it was found that most Kanagawa phenomenon-positive and -negative clinical isolates produced Vp-TDH and Vp-TRH, respectively, but all environmental strains, that were Kanagawa phenomenon-negative, produced neither toxin.Supported by a Grant-in-Aid for Scientific Research and a Grant-in-Aid for Developmental Scientific Research from the Ministry of Education, Science, and Culture of Japan 相似文献
27.
目的 了解长沙地区无偿献血人群隐匿性乙型肝炎病毒感染(occult hepatitis B virus infection,OBI)流行情况,探讨HBV基因型分布特征和S区氨基酸突变的情况。方法 对长沙地区检测结果为HBsAg-/HBV DNA+的无偿献血血液样本进行HBV血清标志物检测,对其中的OBI样本进行HBV病毒载量检测和S区基因扩增,分析血清学标志物抗HBs与病毒载量检出与否的关系,并对扩增产物进行HBV基因分型和突变位点分析。结果 2019年1月—2020年1月长沙地区173 893份无偿献血标本共确认58例OBI样本,OBI流行率为0.033%;共发现7种血清学模式,抗HBc单独阳性最多,占38.98%,所有样本中抗HBc阳性率为89.83%;16例样本能检测出病毒载量,其中14例样本浓度小于100 IU/ml;抗HBs阳性组和阴性组间的病毒载量检出率无统计学差异;75.0%(12/16)样本扩增出S区序列,基因型均为B型,均发生突变,其中11例的HBsAg抗原决定簇及周边主要亲水区域(major hydrophilic region, MHR)发生氨基酸突变。结论 长沙地区无偿献血者中的OBI感染率在全国属于偏低水平;HBV基因型主要是B型,MHR区的氨基酸突变可能是造成OBI的原因,突变有本地特点。 相似文献
28.
目的探索老年患者日间手术全程质量管理模式。方法通过医院病历系统采集2015年-2020年应用老年患者日间手术全程质量管理模式前后患者信息,进行对比分析。结果老年患者应用日间手术全程质量管理模式后,≥65岁老年患者日间手术人数逐年上升,占比从13.52%上升至18.62%,差异有统计学意义(χ2=6.450,P=0.011);日间手术住院时间>5 d的比例从0.72%下降至0.50%,差异有统计学意义(χ2=338.088,P<0.001);不良事件发生率从3.77‰下降至1.56‰,差异有统计学意义(χ2=5.156,P=0.023),其中严重不良事件发生率从2.08‰下降至0.35‰,差异有统计学意义(χ2=7.019,P=0.008)。结论应用日间手术全程质量管理模式能够有效提高老年患者日间手术的安全性,值得借鉴与推广。 相似文献
29.
Ryan Gage Martin Girling-Butcher Ester Joe Moira Smith Cliona Ni Mhurchu Christina McKerchar Viliami Puloka Rachael McLean Louise Signal 《Nutrients》2021,13(1)
Snacking is a common eating behaviour, but there is little objective data about children’s snacking. We aimed to determine the frequency and context of children’s snacking (n = 158; mean age = 12.6 years) by ethnicity, gender, socioeconomic deprivation and body mass index (BMI) children. Participants wore wearable cameras that passively captured images of their surroundings every seven seconds. Images (n = 739,162) were coded for snacking episodes, defined as eating occasions in between main meals. Contextual factors analysed included: snacking location, food source, timing, social contact and screen use. Rates of total, discretionary (not recommended for consumption) and healthful (recommended for consumption) snacking were calculated using negative binomial regression. On average, children consumed 8.2 (95%CI 7.4, 9.1) snacks per day, of which 5.2 (95%CI 4.6, 5.9) were discretionary foods/beverages. Children consumed more discretionary snacks than healthful snacks in each setting and at all times, including 15.0× more discretionary snacks in public spaces and 2.4× more discretionary snacks in schools. Most snacks (68.9%) were sourced from home. Girls consumed more total, discretionary and healthful snacks than boys, and Māori and Pacific consumed fewer healthful snacks than New Zealand (NZ) Europeans. Results show that children snack frequently, and that most snacking involves discretionary food items. Our findings suggest targeting home buying behaviour and environmental changes to support healthy snacking choices. 相似文献
30.
小剂量倍他乐克治疗扩张型心肌病临床观察 总被引:1,自引:0,他引:1
目的观察小剂量倍他乐克治疗扩张性心肌病(DCM)的疗效.方法在常规抗心衰治疗的基础上,加用小剂量倍他乐克6.25mg/d,逐步增加到治疗剂量25~50mg/d,随访观察6个月,治疗前后应用彩色超声多普勒测定左室舒张末及收缩末内径、左室收缩功能,同时测量血压、心率、心胸比率.结果小剂量倍他乐克使扩张性心肌病患者的心率由治疗前92.5±8.1次/分降至71.2±7.2次/分(P<0.01);心功能改善,左室射血分数由治疗前33.7±11.2%提高至41.9±9.8%(P<0.01);左室舒张末内径(LVEDd)由治疗前67.5±5.8mm缩小至58.3±4.9mm(P<0.01),左室收缩末内径(LVEDs)由49.3±5.2降至40.2±5.4(P<0.01).结论长期应用小剂量倍他乐克可改善扩张性心肌病患者的心功能,且付作用少. 相似文献